Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2024-205872

Published: 2024

Journal Articles

Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3 -ITD Patients

Blood (2018) 132 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2018-99-114315

Published: 2018

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

Blood (2017) 130 (Supplement 1): 5386.

https://doi.org/10.1182/blood.V130.Suppl_1.5386.5386

Published: 2017

Journal Articles

The Clinical and Biological Implications of Aberrant Alternative Splicing in Patients with De Novo, Non-M3 Acute Myeloid Leukemia

Chiu Po-Ju, MD, Yi-Tsung Yang, Yu-Chiao Chiu, PhD, Hsin-An Hou, MD, PhD, Jih-Luh Tang, MD,PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Woei Tsai, MD, PhD, Yidong Chen, PhD, Wen-Chien Chou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 1382.

https://doi.org/10.1182/blood.V130.Suppl_1.1382.1382

Published: 2017

Journal Articles

The Clinical Implication and Prognostic Impact of Dynamic Molecular Evolution in Acute Myeloid Leukemia

Jui-Che Chen, MD, Cheng-Hong Tsai, MD, M.Sc., Jih-Luh Tang, MD,PhD, Yuan-Yeh Kuo, PhD, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Chien-Yuan Chen, MD, PhD, Woei Tsai, MD, PhD, Wen-Chien Chou, MD, PhD, Hsin-An Hou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 1300.

https://doi.org/10.1182/blood.V130.Suppl_1.1300.1300

Published: 2017

Journal Articles

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1886.

https://doi.org/10.1182/blood.V130.Suppl_1.1886.1886

Published: 2017

Journal Articles

The Implications of Endoplasmic Reticulum Stress Response in the Prognosis and Pathogenesis of Myelodysplastic Syndrome

Ming-En Lin, MD, Wen-Chien Chou, MD, PhD, Yu-Chiao Chiu, PhD, Mei-Hsuan Tseng, M.Sc., Ming-Chih Liu, Chia-Wen Liu, Jih-Luh Tang, MD,PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Chien-Yuan Chen, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu-Chun Hsu, MD, Hsin-An Hou, MD, PhD, Shang-Ju Wu, MD, PhD, Chien-Ting Lin, MD, Woei Tsai, MD, PhD, Yidong Chen, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 4249.

https://doi.org/10.1182/blood.V130.Suppl_1.4249.4249

Published: 2017

Journal Articles

Prognostic Impacts and Dynamic Changes of Cohesin Complex Gene Mutations in De Novo Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, M.Sc., Hsin-An Hou, MD, PhD, Jih-Luh Tang, MD,PhD, Yuan-Yeh Kuo, PhD, Yu-Chiao Chiu, PhD, Chien-Chin Lin, MD, Liang-In Lin, PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Chien-Yuan Chen, MD, PhD, Woei Tsai, MD, PhD, Wen-Chien Chou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 2582.

https://doi.org/10.1182/blood.V130.Suppl_1.2582.2582

Published: 2017

Journal Articles

The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL)

Feng-Ming Tien, MD, Hsin-An Hou, MD PhD, Chien-Yuan Chen, MD PhD, Wen-Chien Chou, MD PhD, Chi-Cheng Li, MD, Chien-Ting Lin, MD, Ming Yao, MD, Shang-Yi Huang, MD PhD, Bor-Sheng Ko, MD PhD, Szu-Chun Hsu, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Jih-Luh Tang, MD PhD, Hwei-Fang Tien, MD PhD

Blood (2016) 128 (22): 2860.

https://doi.org/10.1182/blood.V128.22.2860.2860

Published: 2016

Journal Articles

Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome

Yi-Tsung Yang, Wen-Chien Chou, MD PhD, Yu-Chiao Chiu, Hsin-An Hou, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, Bor-Sheng Ko, MD PhD, Chien-Yuan Chen, MD PhD, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Hwei-Fang Tien, MD PhD

Blood (2016) 128 (22): 49.

https://doi.org/10.1182/blood.V128.22.49.49

Published: 2016

Journal Articles

Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, Hsin-An Hou, MD PhD, Wen-Chien Chou, MD PhD, Chien-Chin Lin, MD, Chien-Yuan Chen, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, Bor-Sheng Ko, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Hwei-Fang Tien, MD PhD

Blood (2015) 126 (23): 4956.

https://doi.org/10.1182/blood.V126.23.4956.4956

Published: 2015

Journal Articles

The Clinical and Biological Characterization of De Novo Acute Myeloid Leukemia (AML) with GATA2 Mutation

Feng-Ming Tien, MD, Wen-Chien Chou, MD PhD, Hsin-An Hou, MD PhD, Yu-Chiao Chiu, Eric Y. Chuang, Sc.D., Chien-Yuan Chen, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Shang-Yi Huang, Bor-Sheng Ko, Szu-Chun Hsu, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Hwei-Fang Tien, MD PhD

Blood (2015) 126 (23): 3822.

https://doi.org/10.1182/blood.V126.23.3822.3822

Published: 2015

Journal Articles

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Blood (2015) 126 (23): 4240.

https://doi.org/10.1182/blood.V126.23.4240.4240

Published: 2015

Journal Articles

Higher Expression of Suppressor of Cytokine Signaling1 ( SOCS1 ) in the Bone Marrow Is an Unfavorable Prognostic Factor in Adult Patients with De Novo Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, Hwei-Fang Tien, MD PhD, Hsin-An Hou, MD PhD, Wen-Chien Chou, MD PhD, Yan-Jun Lai, Yuan-Yeh Kuo, PhD, Chien-Yuan Chen, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Shang-Yi Huang, Bor-Sheng Ko, MD PhD, Szu-Chun Hsu, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Yao-Chang Chen, MDPhD, Mei-Hsuan Tseng, Chi-Fei Huang

Blood (2014) 124 (21): 1034.

https://doi.org/10.1182/blood.V124.21.1034.1034

Published: 2014

Journal Articles

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Blood (2014) 124 (21): 3458.

https://doi.org/10.1182/blood.V124.21.3458.3458

Published: 2014

Journal Articles

Paired Samples Analyses Of GATA2 mutations During Clinical Follow-Ups In 138 Patients With Acute Myeloid Leukemia-The Mutation Is Unstable During Disease Evolution

Yun-Chu Lin, Hsin-An Hou, MD, Wen-Chien Chou, MD, PhD, Chien-Yuan Chen, MD, Jih-Luh Tang, MD, PhD, Ming Yao, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, Szu-Chun Hsu, MD, Shang-Ju Wu, MD, Woei Tsay, MD, PhD, Yao-Chang Chen, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2013) 122 (21): 2498.

https://doi.org/10.1182/blood.V122.21.2498.2498

Published: 2013

Journal Articles

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, Andrew Spencer, MD, Heather J. Sutherland, MD, PhD, FRCPC, Michael E O'Dwyer, MD, FRCPI, FRCPath, Shang-Yi Huang, MD, PhD, Keith Stewart, MBA, MB, CHB, Ajai Chari, MD, Michael Rosenzwieg, MD, Ajay K. Nooka, MD, MPH, Cara A Rosenbaum, MD, Craig C Hofmeister, MD, Deborah A Smith, PharmD, Joyce M Antal, Ademi Santiago-Walker, Jennifer Gauvin, Joanna B Opalinska, Suzanne Trudel, MD

Blood (2013) 122 (21): 283.

https://doi.org/10.1182/blood.V122.21.283.283

Published: 2013

Journal Articles

Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia

Chieh-Lung Cheng, Hsin-An Hou, Ming-Cheng Lee, Chieh-Yu Liu, Jie-Yang Jhuang, Yan-Jun Lai, Chung-Wu Lin, Huan-Yuan Chen, Fu-Tong Liu, Wen-Chien Chou, Chien-Yuan Chen, Jih-Luh Tang, Ming Yao, Shang-Yi Huang, Bor-Sheng Ko, Shang-Ju Wu, Woei Tsay, Hwei-Fang Tien

Blood (2013) 121 (16): 3172–3180.

https://doi.org/10.1182/blood-2012-07-443762

Published: 2013

Includes: Supplemental data

Journal Articles

DNMT3A mutations in De Novo Myelodysplastic Syndrome: Distinct Clinico-Biological Features and Prognostic Relevance

Blood (2012) 120 (21): 3799.

https://doi.org/10.1182/blood.V120.21.3799.3799

Published: 2012

NARROW

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3 -ITD Patients

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Combined Analysis of 3,664 Patients with Multiple Myeloma (MM) from Latin America (LA) and Asia

The Clinical and Biological Implications of Aberrant Alternative Splicing in Patients with De Novo, Non-M3 Acute Myeloid Leukemia

The Clinical Implication and Prognostic Impact of Dynamic Molecular Evolution in Acute Myeloid Leukemia

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

The Implications of Endoplasmic Reticulum Stress Response in the Prognosis and Pathogenesis of Myelodysplastic Syndrome

Prognostic Impacts and Dynamic Changes of Cohesin Complex Gene Mutations in De Novo Acute Myeloid Leukemia

The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL)

Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome

Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia

The Clinical and Biological Characterization of De Novo Acute Myeloid Leukemia (AML) with GATA2 Mutation

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Higher Expression of Suppressor of Cytokine Signaling1 ( SOCS1 ) in the Bone Marrow Is an Unfavorable Prognostic Factor in Adult Patients with De Novo Acute Myeloid Leukemia

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Paired Samples Analyses Of GATA2 mutations During Clinical Follow-Ups In 138 Patients With Acute Myeloid Leukemia-The Mutation Is Unstable During Disease Evolution

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia

DNMT3A mutations in De Novo Myelodysplastic Syndrome: Distinct Clinico-Biological Features and Prognostic Relevance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only